212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models

International Journal of Molecular Sciences - Switzerland
doi 10.3390/ijms19040925
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

Chondroitin Sulfate Proteoglycan 4 Specific Chimeric Antigen Receptor Therapy for Pediatric Solid Tumors

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2014English

Chondroitin Sulfate Proteoglycan (CSPG)

Science-Business eXchange
2014English

Targeted Downregulation of N-Acetylgalactosamine 4-Sulfate 6-O-Sulfotransferase Significantly Mitigates Chondroitin Sulfate Proteoglycan-Mediated Inhibition

GLIA
Molecular NeuroscienceNeurologyCellular
2011English

Nano-Targeted Delivery of Rad6/Translesion Synthesis Inhibitor for Triple Negative Breast Cancer Therapy

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

Chondroitin Sulfate Proteoglycan 4 and Its Potential as an Antibody Immunotherapy Target Across Different Tumor Types

Frontiers in Immunology
AllergyImmunology
2018English

Targeted Therapies in Triple-Negative Breast Cancer: Failure and Future

Women's Health
Medicine
2015English

Triple-Negative Breast Cancer

2018English

Triple Negative Breast Cancer: Breast Cancer Research in Evolution

Breast Disease
MedicineCancer ResearchOncology
2011English

Targeted Exosomes‐encapsulated Erastin Induced Ferroptosis in the Triple Negative Breast Cancer Cells

Cancer Science
Cancer ResearchMedicineOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy